throbber

`
`HIGHLIGHTS OF PRESCRIBING INFORMATION
`
`These highlights do not include all the information needed to use
`
`
`
`REVLIMID® safely and effectively. See full prescribing information for
`
`
`
`
`REVLIMID.
`
`
`
`REVLIMID (lenalidomide) capsules, for oral use
`
`
`Initial U.S. Approval: 2005
`
`
`
`
`
`•
`
`
`
`
`
` WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC
`
`
`
`
` TOXICITY, and VENOUS and ARTERIAL
`
` THROMBOEMBOLISM
`
`
`See full prescribing information for complete boxed warning.
`
`
`EMBRYO-FETAL TOXICITY
`
`Lenalidomide, a thalidomide analogue, caused limb
`
`•
`abnormalities in a developmental monkey study similar to birth
`
`
`defects caused by thalidomide in humans. If lenalidomide is used
`
`during pregnancy, it may cause birth defects or embryo-fetal
`
`death.
`
`
`Pregnancy must be excluded before start of treatment. Prevent
`
`pregnancy during treatment by the use of two reliable methods
`
`of contraception (5.1).
`
`
`REVLIMID is available only through a restricted distribution
`
`
`
`
`program, called the Lenalidomide REMS program (5.2, 17).
`
`HEMATOLOGIC TOXICITY. REVLIMID can cause significant
`
`neutropenia and thrombocytopenia (5.3).
`
`
`VENOUS AND ARTERIAL THROMBOEMBOLISM
`Significantly increased risk of deep vein thrombosis (DVT) and
`
`•
`
`
` pulmonary embolism (PE), as well as risk of myocardial
` infarction and stroke in patients with multiple myeloma
`
`
` receiving REVLIMID with dexamethasone. Anti-thrombotic
` prophylaxis is recommended (5.4).
`
`
`
`
`
`•
`
`
`•
`
`
`•
`
`
`--------------------------RECENT MAJOR CHANGES---------------------------­
`
`Warnings and Precautions (5.1, 5.2)
`8/2021
`
`
`
`---------------------------INDICATIONS AND USAGE---------------------------­
`REVLIMID is a thalidomide analogue indicated for the treatment of adult
`patients with:
`
`
`• Multiple myeloma (MM), in combination with dexamethasone (1.1).
`
`• MM, as maintenance following autologous hematopoietic stem cell
`
`
`
`transplantation (auto-HSCT) (1.1).
`Transfusion-dependent anemia due to low- or intermediate-1-risk
`
`
`myelodysplastic syndromes (MDS) associated with a deletion 5q
`
`
`abnormality with or without additional cytogenetic abnormalities (1.2).
`• Mantle cell lymphoma (MCL) whose disease has relapsed or progressed
`
`
`after two prior therapies, one of which included bortezomib (1.3).
`
`Previously treated follicular lymphoma (FL), in combination with a
`
`rituximab product (1.4).
`
`
`Previously treated marginal zone lymphoma (MZL), in combination
`
`with a rituximab product (1.5).
`
`
`Limitations of Use:
`
`
`
`REVLIMID is not indicated and is not recommended for the treatment
`•
`
`of patients with chronic lymphocytic leukemia (CLL) outside of
`
`controlled clinical trials (1.4).
`
`
`•
`
`
`•
`
`
`•
`
`
`•
`
`
`•
`
`
`•
`
`
`•
`
`
`•
`
`
`•
`
`
`•
`
`
`•
`
`
`-------------------------------CONTRAINDICATIONS-----------------------------­
`
`
`
`Pregnancy (Boxed Warning, 4.1, 5.1, 8.1).
`•
`
`
`
`Demonstrated severe hypersensitivity to lenalidomide (4.2, 5.9,5.15).
`•
`
`
`-----------------------WARNINGS AND PRECAUTIONS----------------------­
`
`
`Increased Mortality: serious and fatal cardiac adverse reactions occurred
`•
`
`in patients with CLL treated with REVLIMID (5.5).
`
`Second Primary Malignancies (SPM): Higher incidences of SPM were
`
`observed in controlled trials of patients with MM receiving REVLIMID
`
`(5.6).
`
`Increased Mortality: Observed in patients with MM when
`
`pembrolizumab was added to dexamethasone and a thalidomide
`
`analogue (5.7).
`
`
`Hepatotoxicity: Hepatic failure including fatalities; monitor liver
`
`function. Stop REVLIMID and evaluate if hepatotoxicity is suspected
`
`(5.8).
`
`Severe Cutaneous Reactions: Discontinue REVLIMID for severe
`
`
`reactions (5.9).
`Tumor lysis syndrome (TLS) including fatalities: Monitor patients at
`
`risk of TLS (i.e., those with high tumor burden) and take appropriate
`
`precautions (5.10).
`
`
`Tumor flare reaction: Serious tumor flare reactions have occurred
`
`during investigational use of REVLIMID for chronic lymphocytic
`
`leukemia and lymphoma (5.11).
`
`Impaired Stem Cell mobilization: A decrease in the number of CD34+
`
`
`
`cells collected after treatment (> 4 cycles) with REVLIMID has been
`
`reported. Consider early referral to transplant center (5.12).
`
`Early mortality in MCL: Higher rate of early deaths have occurred in
`
`patients with MCL (5.14).
`
`Hypersensitivity: Monitor patients for potential hypersensitivity.
`
`Discontinue REVLIMID for angioedema and anaphylaxis (5.15).
`
`-------------------------------ADVERSE REACTIONS-----------------------------­
`
`
`
`
`
`
`
`
`
`
`
`• MM: Most common adverse reactions (≥20%)include diarrhea, fatigue,
`
`
`anemia, constipation, neutropenia, leukopenia, peripheral edema,
`
`insomnia, muscle cramp/spasms, abdominal pain, back pain, nausea,
`
`asthenia, pyrexia, upper respiratory tract infection, bronchitis,
`
`nasopharyngitis, gastroenteritis, cough, rash, dyspnea, dizziness,
`
`decreased appetite, thrombocytopenia, and tremor (6.1).
`
`
`• MDS: Most common adverse reactions (>15%) include
`
`thrombocytopenia, neutropenia, diarrhea, pruritus, rash, fatigue,
`
`constipation, nausea, nasopharyngitis, arthralgia, pyrexia, back pain,
`
`peripheral edema, cough, dizziness, headache, muscle cramp, dyspnea,
`
`pharyngitis, and epistaxis (6.1).
`
`Non-Hodgkin’s Lymphoma (NHL: MCL, FL or MZL): Most common
`
`
`
`
`
`
`adverse reactions (≥15%)included neutropenia,thrombocytopenia,
`
`anemia, leukopenia, diarrhea, constipation, nausea, fatigue, pyrexia,
`
`
`cough, upper respiratory tract infection, and rash (6.1).
`
`
`
`To report SUSPECTED ADVERSE REACTIONS contact Celgene
`
`Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or
`
`www.fda.gov/medwatch.
`
`
`-------------------------------DRUG INTERACTIONS-----------------------------­
`
`
`Digoxin: Monitor digoxin plasma levels periodically due to increased
`•
`
`Cmax and AUC with concomitant REVLIMID therapy (7.1).
`
`Concomitant use of erythropoietin stimulating agents or estrogen
`
`containing therapies with REVLIMID may increase the risk of
`
`
`thrombosis (7.2).
`
`
`--------------------------USE IN SPECIFIC POPULATIONS--------------------­
`
`Lactation: Advise not to breastfeed (8.2).
`
`
`•
`
`See 17 for PATIENT COUNSELING INFORMATION and Medication
`
`
`
`
`
`Guide
`
`
`
`
`
`Revised: 8/2021
`
`
`
`
`
`-----------------------DOSAGE AND ADMINISTRATION----------------------­
`
`
`
`• MM combination therapy: 25 mg once daily orally on Days 1-21 of
`
`
`repeated 28-day cycles.(2.1).
`
`
`
`• MM maintenance therapy following auto-HSCT: 10 mg once daily
`
`continuously on Days 1-28 of repeated 28-day cycles (2.1).
`
`
`
`• MDS: 10 mg once daily (2.2).
`• MCL: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles
`
`
`
`
`
`(2.3).
`
`FL or MZL: 20 mg once daily orally on Days 1-21 of repeated 28-day
`
`cycles for up to 12 cycles (2.4).
`
`Renal impairment: Adjust starting dose based on the creatinine
`
`clearance value (2.6).
`
`For concomitant therapy doses, see Full Prescribing Information (2.1,
`
`2.4, 14.1, 14.4).
`
`----------------------DOSAGE FORMS AND STRENGTHS--------------------­
`
`
`
`Capsules: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg (3).
`
`
`
`
`•
`
`
`•
`
`
`•
`
`Reference ID: 4850105
`
`
`
`
`
`
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
` FULL PRESCRIBING INFORMATION: CONTENTS*
`
` WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC
`
`
`
` TOXICITY, and VENOUS and ARTERIAL THROMBOEMBOLISM
` INDICATIONS AND USAGE
`
`
`
` 1
` 1.1 Multiple Myeloma
`
`
`
`
`
`
` 1.2 Myelodysplastic Syndromes
`
`
`
` 1.3 Mantle Cell Lymphoma
`
`
`
`
` 1.4 Follicular Lymphoma
`
`
`
`
` 1.5 Marginal Zone Lymphoma
`
`
`
` 1.6 Limitations of Use
`
`
` 2
` DOSAGE AND ADMINISTRATION
`
`
`
` 2.1 Recommended Dosage for Multiple Myeloma
`
`
` 2.2 Recommended Dosage for Myelodysplastic Syndromes
`
`
` 2.3 Recommended Dosage for Mantle Cell Lymphoma
`
`
`
` 2.4 Recommended Dosage for Follicular Lymphoma or Marginal Zone
`
`
` Lymphoma
`
`
` 2.5 Dosage Modifications for Non-Hematologic Adverse Reactions
`
`
` 2.6 Recommended Dosage for Patients with Renal Impairment
`
`
`
` 2.7 Administration
`
`
` DOSAGE FORMS AND STRENGTHS
`
` CONTRAINDICATIONS
`
`
` 4.1 Pregnancy
`
`
` 4.2 Severe Hypersensitivity Reactions
`
` 5 WARNINGS AND PRECAUTIONS
`
`
`
` 5.1 Embryo-Fetal Toxicity
`
`
` 5.2 LenalidomideREMS Program
`
`
`
` 5.3 Hematologic Toxicity
`
`
`
`
` 5.4 Venous and Arterial Thromboembolism
`
`
`
` 5.5 Increased Mortality in Patients with CLL
`
`
` 5.6 Second Primary Malignancies
`
`
`
` 5.7 Increased Mortality in Patients with MM When Pembrolizumab Is
`
`
`
` Added to a Thalidomide Analogue and Dexamethasone
`
`
`
` 5.8 Hepatotoxicity
`
`
` 5.9 Severe Cutaneous Reactions
`
` 5.10 Tumor Lysis Syndrome
`
`
`
`
` 5.11 Tumor Flare Reaction
`
`
`
` 5.12 Impaired Stem Cell Mobilization
`
` 5.13 Thyroid Disorders
`
`
` 5.14 Early Mortality in Patients with MCL
`
`
`
` 5.15 Hypersensitivity
`
`
`
`
`
`
`
`
`
`
` 3
`
` 4
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 6
`
`
`
`
`
` 7
`
`
`
` 8
`
`
`
`
`
` ADVERSE REACTIONS
`
`
`
` 6.1 Clinical Trials Experience
`
`
`
` 6.2 Postmarketing Experience
`
` DRUG INTERACTIONS
`
`
`
` 7.1 Digoxin
`
`
` 7.2 Concomitant Therapies That May Increase the Risk of Thrombosis
`
`
` 7.3 Warfarin
`
`
` USE IN SPECIFIC POPULATIONS
`
`
` 8.1 Pregnancy
`
`
` 8.2 Lactation
`
`
`
` 8.3 Females and Males of Reproductive Potential
`
`
` 8.4 Pediatric Use
`
`
`
` 8.5 Geriatric Use
`
`
`
` 8.6 Renal Impairment
`
`
` 10 OVERDOSAGE
`
`
` 11 DESCRIPTION
`
`
` 12 CLINICAL PHARMACOLOGY
`
`
` 12.1 Mechanism of Action
`
`
` 12.2 Pharmacodynamics
`
`
`
` 12.3 Pharmacokinetics
`
`
` 13 NONCLINICAL TOXICOLOGY
`
`
`
` 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`
` 14 CLINICAL STUDIES
`
`
`
`
` 14.1 Multiple Myeloma
`
`
` 14.2 Myelodysplastic Syndromes (MDS) with a Deletion 5q
`
`
` Cytogenetic Abnormality
`
`
`
` 14.3 Mantle Cell Lymphoma
`
`
` 14.4 Follicular and Marginal Zone Lymphoma
`
` 15 REFERENCES
`
`
`
` 16 HOW SUPPLIED/STORAGE AND HANDLING
`
`
` 16.1 How Supplied
`
`
` 16.2 Storage
`
`
`
`
` 16.3 Handling and Disposal
`
`
` 17 PATIENT COUNSELING INFORMATION
`
`
`*Sections or subsections omitted from the full prescribing information are not
`
` listed.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Reference ID: 4850105
`
`
`2
`
`

`

`
`
`
`
`
`
` FULL PRESCRIBING INFORMATION
`
`
` WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, and VENOUS and ARTERIAL THROMBOEMBOLISM
`
`Embryo-Fetal Toxicity
`
`
`
`
`
`Do not use REVLIMID during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental
`
`monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is used
`
`
`during pregnancy, it may cause birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy
`tests before starting REVLIMID® treatment. Females of reproductive potential must use 2 forms of contraception or continuously
`
`
`
`abstain from heterosexual sex during and for 4 weeks after REVLIMID treatment [see Warnings and Precautions (5.1), and Medication
`
`Guide (17)]. To avoid embryo-fetal exposure to lenalidomide, REVLIMID is only available through a restricted distribution program,
`
`
`the Lenalidomide REMS program (5.2).
`
`
`
`
`
`Information about the Lenalidomide REMS program is available at www.celgeneriskmanagement.com or by calling the manufacturer’s
`
`
`
`
`toll-free number 1-888-423-5436.
`
`
`
`Hematologic Toxicity (Neutropenia and Thrombocytopenia)
`
`
`
`
`REVLIMID can cause significant neutropenia and thrombocytopenia. Eighty percent of patients with del 5q myelodysplastic syndromes
`
`
`
`had to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction.
`
`
`
`Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for del 5q myelodysplastic
`
`
`
`syndromes should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter.
`
`Patients may require dose interruption and/or reduction. Patients may require use of blood product support and/or growth factors [see
`
`
`Dosage and Administration (2.2)].
`
`
`
`
`Venous and Arterial Thromboembolism
`
`REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as
`
`
`
`risk of myocardial infarction and stroke in patients with multiple myeloma who were treated with REVLIMID and dexamethasone
`therapy. Monitor for and advise patients about signs and symptoms of thromboembolism. Advise patients to seek immediate medical
`
`
`care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Thromboprophylaxis is recommended and
`
`the choice of regimen should be based on an assessment of the patient’s underlying risks [see Warnings and Precautions (5.4)].
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`INDICATIONS AND USAGE
`1
`
`
`Multiple Myeloma
`1.1
`
`REVLIMID in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM).
`
`
`REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).
`
`
`1.2
`Myelodysplastic Syndromes
`
`
`
`REVLIMID is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS)
`
`associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
`
`
`1.3
`Mantle Cell Lymphoma
`
`
`REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of
`
`which included bortezomib.
`
`
`Follicular Lymphoma
`1.4
`
`REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).
`
`
`1.5
`Marginal Zone Lymphoma
`
`REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).
`
`
`1.6
`Limitations of Use
`
`REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5)].
`
`
`
`
`DOSAGE AND ADMINISTRATION
`2
`
`
`Recommended Dosage for Multiple Myeloma
`2.1
`
`REVLIMID Combination Therapy
`The recommended starting dose of REVLIMID is 25 mg orally once daily on Days 1-21 of repeated 28-day cycles in combination with dexamethasone. Refer to
`
`Section 14.1 for specific dexamethasone dosing. For patients greater than 75 years old, the starting dose of dexamethasone may be reduced [see Clinical Studies
`
`
`(14.1)]. Treatment should be continued until disease progression or unacceptable toxicity.
`
`
`In patients who are not eligible for auto-HSCT, treatment should continue until disease progression or unacceptable toxicity. For patients who are auto-HSCT-eligible,
`
`hematopoietic stem cell mobilization should occur within 4 cycles of a REVLIMID-containing therapy [see Warnings and Precautions (5.12)].
`
`
`
`
`Dose Adjustments for Hematologic Toxicities During MM Treatment
`
`
`Dose modification guidelines, as summarized in Table 1 below, are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4
`toxicity judged to be related to REVLIMID.
`
`
`Reference ID: 4850105
`
`
`3
`
`

`

`
`
` Table 1: Dose Adjustments for Hematologic Toxicities for MM
`
` Platelet counts
`
`Thrombocytopenia in MM
`
`
`
`
` When Platelets
`
` Fall below 30,000/mcL
`
`
` Return to at least 30,000/mcL
`
`
`
`
` For each subsequent drop below 30,000/mcL
`
` Return to at least 30,000/mcL
`
`
`
` Absolute Neutrophil counts (ANC)
`
` Neutropenia in MM
` When Neutrophils
`
`
`
`
` Fall below 1000/mcL
`
`
`
`
`
` Return to at least 1,000/mcL and neutropenia is the only toxicity
`
`
`
`
`
` Return to at least 1,000/mcL and if other toxicity
`
`
` For each subsequent drop below 1,000/mcL
`
` Return to at least 1,000/mcL
`
`
`
`
`
` Recommended Course
`
` Days 1-21 of repeated 28-day cycle
`
`
` Interrupt REVLIMID treatment, follow CBC weekly
`
` Resume REVLIMID at next lower dose. Do not dose
`
`
` below 2.5 mg daily
` Interrupt REVLIMID treatment
`
` Resume REVLIMID at next lower dose. Do not dose
`
` below 2.5 mg daily
`
`
`
` Recommended Course
`
` Days 1-21 of repeated 28-day cycle
`
` Interrupt REVLIMID treatment, follow CBC
`
`
` weekly
`Resume REVLIMID at 25 mg daily or initial
`
` starting dose
` Resume REVLIMID at next lower dose. Do not
`
` dose below 2.5 mg daily
` Interrupt REVLIMID treatment
`
` Resume REVLIMID at next lower dose. Do not
`
` dose below 2.5 mg daily
`
`
`
`
`
`
`REVLIMID Maintenance Therapy Following Auto-HSCT
`
`Following auto-HSCT, initiate REVLIMID maintenance therapy after adequate hematologic recovery (ANC at least 1000/mcL and/or platelet counts at least
`
`
`
`75,000/mcL). The recommended starting dose of REVLIMID is 10 mg once daily continuously (Days 1-28 of repeated 28-day cycles) until disease progression or
`
`unacceptable toxicity. After 3 cycles of maintenance therapy, the dose can be increased to 15 mg once daily if tolerated.
`
`
`Dose Adjustments for Hematologic Toxicities During MM Treatment
`
`Dose modification guidelines, as summarized in Table 2 below, are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4
`
`
`toxicity judged to be related to REVLIMID.
`
`Table 2: Dose Adjustments for Hematologic Toxicities for MM
`
`Platelet counts
`
`
`Thrombocytopenia in MM
`
` When Platelets
` Fall below 30,000/mcL
`
`
` Return to at least 30,000/mcL
`
`
` Recommended Course
`
` Interrupt REVLIMID treatment, follow CBC weekly
`
` Resume REVLIMID at next lower dose, continuously
`
`
` for Days 1-28 of repeated 28-day cycle
`Interrupt REVLIMID treatment. Do not dose below 5
`
`
` mg daily for Day 1 to 21 of 28 day cycle
`
`
` Resume REVLIMID at 5 mg daily for Days 1 to 21of
`
`28-day cycle. Do not dose below 5 mg daily for Day 1
`
`
` to 21 of 28 day cycle
`
`
`
` If at the 5 mg daily dose,
`
`
`
` For a subsequent drop below 30,000/mcL
`
` Return to at least 30,000/mcL
`
`
`
`
`
`
`Absolute Neutrophil counts (ANC)
`
`Neutropenia in MM
` When Neutrophils
`
` Fall below 500/mcL
`
`
`Return to at least 500/mcL
`
`
`
` If at 5 mg daily dose,
`
`
` For a subsequent drop below 500/mcL
`
`
`Return to at least 500/mcL
`
`
`
` Recommended Course
`
` Interrupt REVLIMID treatment, follow CBC weekly
`
` Resume REVLIMID at next lower dose,
`
`continuously for Days 1-28 of repeated 28-day cycle
` Interrupt REVLIMID treatment. Do not dose below 5
`
`
`
` mg daily for Days 1 to 21 of 28-day cycle
`
`
` Resume REVLIMID at 5 mg daily for Days 1 to 21 of
` 28-day cycle. Do not dose below 5 mg daily for Days
`
`
` 1 to 21 of 28-day cycle
`
`
`Recommended Dosage for Myelodysplastic Syndromes
`2.2
`
`
`
`
`The recommended starting dose of REVLIMID is 10 mg daily. Treatment is continued or modified based upon clinical and laboratory findings. Continue treatment
`
`
`until disease progression or unacceptable toxicity.
`
`
`Dose Adjustments for Hematologic Toxicities During MDS Treatment
`
`Patients who are dosed initially at 10 mg and who experience thrombocytopenia should have their dosage adjusted as follows:
`
`
`
`Reference ID: 4850105
`
`
`4
`
`

`

`
`
`
`
` Platelet counts
`
` If thrombocytopenia develops WITHIN 4 weeks of starting treatment at 10 mg daily in MDS
`
`
`
`
` Recommended Course
`
` Interrupt REVLIMID treatment
`
` Resume REVLIMID at 5 mg daily
`
`
`
`
` Recommended Course
`
` Interrupt REVLIMID treatment
`
` Resume REVLIMID at 5 mg daily
`
`
`
`
` Resume REVLIMID at 5 mg daily
`
`
`
`
`
`
`
`
`
`
`
`
`
` Resume REVLIMID at 5 mg daily
`
`
`
`
`
` Recommended Course
`
` Interrupt REVLIMID treatment
`
`
`
`
` Resume REVLIMID at 2.5 mg daily
`
`
`
`
`
`
`
` If baseline is at least 100,000/mcL
`
`
`
` When Platelets
` Fall below 50,000/mcL
`
`
` Return to at least 50,000/mcL
`
`
`
` If baseline is below 100,000/mcL
`
` When Platelets
`
` Fall to 50% of the baseline value
`
` If baseline is at least 60,000/mcL and
`
` returns to at least 50,000/mcL
` If baseline is below 60,000/mcL and
`
` returns to at least 30,000/mcL
`
` If thrombocytopenia develops AFTER 4 weeks of starting treatment at 10 mg daily in MDS
`
`
` When Platelets
` Recommended Course
`
` Fall below 30,000/mcL or below 50,000/mcL
`
` Interrupt REVLIMID treatment
`
`
` with platelet transfusions
`Return to at least 30,000/mcL
`
` (without hemostatic failure)
` Patients who experience thrombocytopenia at 5 mg daily should have their dosage adjusted as follows:
`
` If thrombocytopenia develops during treatment at 5 mg daily in MDS
`
` When Platelets
` Fall below 30,000/mcL or below 50,000/mcL
`
`
` with platelet transfusions
`
` Return to at least 30,000/mcL
`
` (without hemostatic failure)
`
` Patients who are dosed initially at 10 mg and experience neutropenia should have their dosage adjusted as follows:
`
` Absolute Neutrophil counts (ANC)
` If neutropenia develops WITHIN 4 weeks of starting treatment at 10 mg daily in MDS
`
`
`
`
` If baseline ANC is at least 1,000/mcL
`
`
`
` When Neutrophils
` Fall below 750/mcL
`
` Return to at least 1,000/mcL
`
`
`
` If baseline ANC is below 1,000/mcL
`
` When Neutrophils
`
` Fall below 500/mcL
`
` Return to at least 500/mcL
`
`
`
` Recommended Course
`
` Interrupt REVLIMID treatment
`
` Resume REVLIMID at 5 mg daily
`
`
` Recommended Course
`
` Interrupt REVLIMID treatment
`
` Resume REVLIMID at 5 mg daily
`
`
`
`If neutropenia develops AFTER 4 weeks of starting treatment at 10 mg daily in MDS
`
`
`
`
`
` Recommended Course
`
` Interrupt REVLIMID treatment
`
`
` When Neutrophils
`
` Fall below 500/mcL for at least 7 days or below 500/mcL
`
` associated with fever (at least 38.5°C)
` Resume REVLIMID at 5 mg daily
`
` Return to at least 500/mcL
`
` Patients who experience neutropenia at 5 mg daily should have their dosage adjusted as follows:
`
` If neutropenia develops during treatment at 5 mg daily in MDS
`
`
`
`
`
`
` When Neutrophils
`
` Fall below 500/mcL for at least 7 days or below 500/mcL
`
` associated with fever (at least 38.5°C)
`
` Return to at least 500/mcL
`
` Recommended Course
`
`
` Interrupt REVLIMID treatment
`
`
`
`
` Resume REVLIMID at 2.5 mg daily
`
`
`
`
`
`
`
`Reference ID: 4850105
`
`
`5
`
`

`

` Recommended Dosage for Mantle Cell Lymphoma
` 2.3
`
`
`
` The recommended starting dose of REVLIMID is 25 mg/day orally on Days 1-21 of repeated 28-day cycles for relapsed or refractory mantle cell lymphoma.
` Treatment should be continued until disease progression or unacceptable toxicity.
`
`
`
`Treatment is continued, modified or discontinued based upon clinical and laboratory findings.
`
`Dose Adjustments for Hematologic Toxicities During MCL Treatment
`Dose modification guidelines as summarized below are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicities
`
`considered to be related to REVLIMID.
`
`Platelet counts
`
`
`Thrombocytopenia during treatment in MCL
`
`
`
`
`
`
`
`
`
`
` Recommended Course
`
` Interrupt REVLIMID treatment and follow CBC weekly
`
` Resume REVLIMID at 5 mg less than the previous dose. Do
`
` not dose below 5 mg daily
`
`
`
`
`
`
` Recommended Course
`
` Interrupt REVLIMID treatment and follow CBC weekly
`
`
`
`
`
`
`
` When Platelets
`
`
` Fall below 50,000/mcL
`
` Return to at least 50,000/mcL
`
`
`
`
`
`
` Absolute Neutrophil counts (ANC)
`
` Neutropenia during treatment in MCL
`
` When Neutrophils
`
`
` Fall below 1000/mcL for at least 7 days
`
` OR
` Falls below 1,000/mcL with an associated temperature at least
`
` 38.5°C
`
` OR
` Falls below 500/mcL
`
` Return to at least 1,000/mcL
`
`
`
`
`
`
`
`
`Recommended Dosage for Follicular Lymphoma or Marginal Zone Lymphoma
`2.4
`
`The recommended starting dose of REVLIMID is 20 mg orally once daily on Days 1-21 of repeated 28-day cycles for up to 12 cycles of treatment in combination with
`
`a rituximab-product. Refer to Section 14.4 for specific rituximab dosing from the AUGMENT trial. For dose adjustments due to toxicity with rituximab, refer to the
`
`product prescribing information.
`
`
`Dose Adjustments for Hematologic Toxicities during FL or MZL Treatment
`
`
`
`Dose modification guidelines, as summarized below, are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicity judged
`
`to be related to REVLIMID.
`
`Platelet counts
`
`Thrombocytopenia during treatment in FL or MZL
` When Platelets
`
`
` Fall below 50,000/mcL
`
` Return to at least 50,000/mcL
`
`
`
`
`
`
`
`
`
`Absolute Neutrophil counts (ANC)
`
`Neutropenia during treatment in FL or MZL
`
` When Neutrophils
` Fall below 1,000/mcL for at least 7 days
`
` OR
`
`
`Falls below 1,000/mcL with an associated temperature at least
`
`38.5°C
`
`OR
` Falls below 500 /mcL
`
` Return to at least 1,000/mcL
`
`
`
`
`
`
`
`
` Resume REVLIMID at 5 mg less than the previous dose. Do
`
` not dose below 5 mg daily
`
`
`
`
`
`
`
` Recommended Course
`
` Interrupt REVLIMID treatment and follow CBC weekly.
`
`
` If patient starting dose was 20 mg daily, resume REVLIMID
`
` at 5 mg less than the previous dose. Do not dose below 5 mg
`
`daily.
`
`
`
` If patient starting dose was 10 mg daily, resume at 5 mg less
`
` than previous dose. Do not dose below 2.5 mg daily.
`
`
` Recommended Course
`
` Interrupt REVLIMID treatment and follow CBC weekly.
`
`
`
`
`
`If patient starting dose was 20 mg daily, resume REVLIMID
`
` at 5 mg less than the previous dose. Do not dose below 5 mg
`
` daily.
`
`
`
`Reference ID: 4850105
`
`
`6
`
`

`

`
`If patient starting dose was 10 mg daily, resume at 5 mg less
`
`
` than previous dose. Do not dose below 2.5 mg daily.
`
`
`
`
`
`
`Dosage Modifications for Non-Hematologic Adverse Reactions
`2.5
`
`
`
`For non-hematologic Grade 3/4 toxicities judged to be related to REVLIMID, hold treatment and restart at the physician's discretion at next lower dose level when
`
`toxicity has resolved to Grade 2 or below.
`
`Permanently discontinue REVLIMID for angioedema, anaphylaxis, Grade 4 rash, skin exfoliation, bullae, or any other severe dermatologic reactions [see Warnings and
`
`
`Precautions (5.9, 5.15)].
`
`
`Recommended Dosage for Patients with Renal Impairment
`2.6
`
`
`
`The recommendations for dosing patients with renal impairment are shown in the following table [see Clinical Pharmacology (12.3)].
`
`
` Renal Function
`
` (Cockcroft-Gault)
`
`
`
`
`Table 3: Dose Adjustments for Patients with Renal Impairment
` Dose in REVLIMID Combination
` Dose in REVLIMID Combination
`
`
`
` Therapy for MM and MCL
`
`
` Therapy for FL and MZL
`
`
`
`
`
`
`
`CLcr 30 to 60 mL/min
` CLcr below 30 mL/min (not requiring
`
` dialysis)
` CLcr below 30 mL/min (requiring
`
` dialysis)
`
`
`
` 10 mg once daily
`
` 15 mg every other day
`
`
`
` 5 mg once daily. On dialysis days,
`
`
` administer the dose following
`
` dialysis.
`
`
`
`
`
`
` 10 mg once daily
` 5 mg once daily
`
`
`
` 5 mg once daily. On dialysis days,
`
`
` administer the dose following
`
` dialysis.
`
`
`
`
`DOSAGE FORMS AND STRENGTHS
`
`
`REVLIMID Combination Therapy for MM: For CLcr of 30 to 60 mL/min, consider escalating the dose to 15 mg after 2 cycles if the patient tolerates the 10 mg dose of
`
`
`
`
`
`lenalidomide without dose-limiting toxicity.
`
`
`REVLIMID Maintenance Therapy Following Auto-HSCT for MM and for MCL and MDS: Base subsequent REVLIMID dose increase or decrease on individual
`
`
`patient treatment tolerance [see Dosage and Administration (2.1- 2.3)].
`
`
`
`
`
`
`REVLIMID Combination Therapy for FL or for MZL: For patients with CLcr of 30 to 60 mL/min, after 2 cycles, the REVLIMID dose may be increased to 15mg
`
`
`orally if the patient has tolerated therapy.
`
`
`Administration
`2.7
`
`
`
`
`Advise patients to take REVLIMIDorally at about the same time each day, either with or without food. Advise patients to swallow REVLIMID capsules whole with
`
`water and not to open, break, or chew them.
`
`
`
`3
`
`
`Capsules:
`
`
` Dose in REVLIMID Maintenance
`
`
` Therapy Following Auto-HSCT for
`
`
`
` MM and for MDS
`
`
` 5 mg once daily
` 2.5 mg once daily
`
`
`2.5 mg once daily. On dialysis days,
`
` administer the dose following
`
` dialysis.
`
`
`
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`
`2.5 mg, white and blue-green opaque hard capsules imprinted “REV” on one half and “2.5 mg” on the other half in black ink
`
`
`5 mg, white opaque capsules imprinted “REV” on one half and “5 mg” on the other half in black ink
`
`10 mg, blue/green and pale yellow opaque capsules imprinted “REV” on one half and “10 mg” on the other half in black ink
`
`15 mg, powder blue and white opaque capsules imprinted “REV” on one half and “15 mg” on the other half in black ink
`
`20 mg, powder blue and blue-green opaque hard capsules imprinted “REV” on one half and “20 mg” on the other half in black ink
`
`25 mg, white opaque capsules imprinted “REV” on one half and “25 mg” on the other half in black ink
`
`
`
`
`
`CONTRAINDICATIONS
`4
`
`
`Pregnancy
`4.1
`
`
`
`REVLIMID can cause fetal harm when administered to a pregnant female. Limb abnormalities were seenin the offspring of monkeys that were dosed with
`
`
`lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide’s structural
`
`similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [see Boxed Warning].If this drug is used during
`
`
`
`
`pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions (5.1,
`
`
`5.2), Use in Special Populations (8.1, 8.3)].
`
`
`Severe Hypersensitivity Reactions
`4.2
`
`REVLIMID is contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to
`
`lenalidomide [see Warnings and Precautions (5.9, 5.15)].
`
`
`
`
`
`
`WARNINGS AND PRECAUTIONS
`5
`
`
`Embryo-Fetal Toxicity
`5.1
`
`REVLIMID is a thalidomide analogue and is contraindicated for use during pregnancy. Thalidomide is a known human teratogen that causes life-threatening human
`
`
`
`
`birth defects or embryo-fetal death [see Use in Specific Populations (8.1)]. An embryo-fetal development study in monkeys indicates that lenalidomide produced
`
`
`malformations in the offspring of female monkeys who received the drug during pregnancy, similar to birth defects observed in humans following exposure to
`
`thalidomide during pregnancy.
`
`Reference ID: 4850105
`
`
`7
`
`

`

`
`REVLIMID is only available through the Lenalidomide REMS program [see Warnings and Precautions (5.2)].
`
`
`
`
`
`
`
`Females of Reproductive Potential
`
`
`Females of reproductive potential must avoid pregnancy for at least 4 weeks before beginning REVLIMID therapy, during therapy, during dose interruptions and for at
`
`least 4 weeks after completing therapy.
`
`Females must commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control, beginning 4 weeks prior to
`
`
`
`initiating treatment with REVLIMID, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of REVLIMID therapy.
`
`
`
`
`
`Two negative pregnancy tests must be obtained prior to initiating therapy. The first test should be performed within 10-14 days and the second test within 24 hours
`
`
`prior to prescribing REVLIMID therapy and then weekly during the first month, then monthly thereafter in females with regular menstrual cycles or every 2 weeks in
`
`
`females with irregular menstrual cycles [see Use in Specific Populations (8.3)].
`
`
`
`
`
`Males
`
`
`
`Lenalidomide is present in the semen of patients receiving the drug. Therefore, males must always use a latex or synthetic condom during any sexual contact with
`
`
`females of reproductive potential while taking REVLIMID and for up to 4 weeks after discontinuing REVLIMID, even if they have undergone a successful vasectomy.
`
`
`
`Male patients taking REVLIMID must not donate sperm [see Use in Specific Populations (8.3)].
`
`
`
`Blood Donation
`
`Patients must not donate blood during treatment with REVLIMID and for 4 weeks following discontinuation of the drug because the blood might be given to a pregnant
`
`female patient whose fetus must not be exposed to REVLIMID.
`
`
`
`5.2
`Lenalidomide REMS Program
`
`
`
`
`
`Because of the embryo-fetal risk [see Warnings and Precautions (5.1)], REVLIMID is available only through a restricted program under a Risk Evaluation and
`
`
`
`Mitigation

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket